302. ALEMTUZUMAB FOR RELAPSING AND REFRACTORY PRIMARY SYSTEMIC VASCULITIS – A TRIAL OF EFFICACY AND SAFETY (ALEVIATE): A RANDOMISED OPEN-LABEL PHASE II CLINICAL TRIAL | Zendy

AI Assistant Blog Pricing

302. ALEMTUZUMAB FOR RELAPSING AND REFRACTORY PRIMARY SYSTEMIC VASCULITIS – A TRIAL OF EFFICACY AND SAFETY (ALEVIATE): A RANDOMISED OPEN-LABEL PHASE II CLINICAL TRIAL

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.